Acrobiosystems Co

Acrobiosystems Co Asset Turnover

The Asset Turnover Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 0.28. In the previous year, Asset Turnover Ratio was 0.22 — a change of 25.83% (higher).

Asset Turnover

0.28

YoY

25.83%

Last updated:

Asset Turnover Ratio of Acrobiosystems Co is 2025 0.28 . Asset Turnover Ratio of Acrobiosystems Co was 2024 0.22 . It decreases by 25.83% higher compared to the previous year.

The Acrobiosystems Co Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Turnover
Date
Asset Turnover
Jan 1, 2018
0.84 CNY
Jan 1, 2019
0.91 CNY
Jan 1, 2020
1.02 CNY
Jan 1, 2021
0.15 CNY
Jan 1, 2022
0.17 CNY
Jan 1, 2023
0.19 CNY
Jan 1, 2024
0.22 CNY
Jan 1, 2025
0.28 CNY
The Acrobiosystems Co Asset Turnover history
YEARAsset TurnoverYoY
0.28+25.83%
0.22+14.53%
0.19+11.43%
0.17+14.62%
0.15-85.18%
1.02+12.11%
0.91+8.81%
0.84—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Asset Turnover Ratio of Acrobiosystems Co is 0.28 in 2025.

Asset Turnover Ratio of Acrobiosystems Co changed from 0.22 to 0.28, representing a 25.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Asset Turnover Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Asset turnover measures how efficiently a company uses its assets to generate revenue. Higher ratios indicate more efficient asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Asset Turnover Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Asset Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Asset Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co